Analystreport

Ovid Therapeutics (OVID) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.

Ovid Therapeutics Inc.  (OVID) 
Last ovid therapeutics inc. earnings: 3/11 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.ovidrx.com